Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
  • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
  • C07D513/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
  • C07D517/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains two hetero rings
  • C07D517/04—Ortho-condensed systems

Definitions

• the present invention relates to new methylpiperazinoazepine derivatives and their non-toxic salts, as well as to the preparation of these new compounds and to their therapeutic use.
• the new methylpiperazinoazepines of the invention are represented by the general formula (I):
• X represents an oxygen, sulfur or selenium atom or a
• R. represents a hydrogen atom, a halogen atom or an alkyl group of 1 to carbon atoms, branched or not;
• R- represents a hydrogen atom, a halogen atom or an alkyl group of 1 to 4 carbon atoms, branched or not;
• NOT . represents a benzenic nucleus and N_ a pyridine nucleus or vice versa, on the condition that, when R, and R2 represent hydrogen and X represents sulfur, oxygen or an NH group, N. either pyridine and N- benzenic, nitrogen pv ⁇ dini- that cannot be in position of, and N. and N_ can also both be benzene when X represents a selenium atom.
• the methylpiperazinoazepine derivatives of the present invention are represented by the general formula (I).
• the term “alkyl group of 1 to carbon atoms, branched or not,” means methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl groups.
• the term halogen covers chlorine, fluorine, iodine and bromine.
• Preferred classes of compounds according to formula (I) are, in particular, that in which R. represents a hydrogen atom, a chlorine atom, a fluorine atom or a methyl group and that in which R- represents a hydrogen atom or a chlorine atom.
• R. represents a hydrogen atom, a chlorine atom, a fluorine atom or a methyl group and that in which R- represents a hydrogen atom or a chlorine atom.
• R. represents hydrogen, chlorine, fluorine or methyl and, simultaneously, R_ represents hydrogen or chlorine.
• the derivatives according to formula (I) which can be in the form of non-toxic salts, are in particular salts of inorganic acids, such as hydrochlorides, hydrobromides, phosphates, sulfates, or organic acids, such as acetates, citrates, maleates, fumarates and methanesulfonates.
• inorganic acids such as hydrochlorides, hydrobromides, phosphates, sulfates, or organic acids, such as acetates, citrates, maleates, fumarates and methanesulfonates.
• Examples of derivatives according to the invention are: 1 l- (4-methylpiperazin-1-yl) -5H-pyrido (4,3-b) benzo-1,5-diazepine;
• the new compounds according to the invention can be prepared according to the general process forming the subject of the present invention from known or easily synthesized azepinones corresponding to formula (II):
• azepinone namely 10H, 11H-dibenzo (b, f) 1,4-selenazepine-1 l-one could also be prepared from dibromo-2,2'-benzanilide.
• 150 ml of dry dimethylformamide, 0.015 mole of selenium, 0.050 mole of sodium are introduced into a flask.
• the mixture is brought to 100 ° C., with stirring for hours.
• 0.025 mole of dibromo-2,2'-benzanilide is added and the mixture is left stirring for 20 hours at 100-110 ° C.
• the solution is poured onto a mixture of hydrochloric acid and ice.
• the precipitate is filtered.
• the product obtained is treated with boiling alcohol and filtered.
• the derivative is recrystallized from a mixture of dimethylformamide and water. Melting point of 275 ° C.
• 3-carboxylic (0.1 mole) is poured little by little over a solution of 2-amino- -choro-phenoI (0.2 mole) in tetrahydrofuran (150 ml). The mixture is left under stirring at reflux for one hour. We diluted with 1 liter of water. The precipitate formed is collected, washed and dried. The raw product is used as is for the following handling.
• Oxazepine is prepared by treating the amide with the theoretical amount of sodium ethylate in absolute alcohol. By evaporation of the solvent, the sodium salt is isolated. By heating the latter at reflux for
• the phenolic ester of 5-chlorosalicylic acid is prepared by heating at reflux 0.1 mole of phenol and 0.1 mole of 5-chlorosalicylic acid in the presence of an excess of OPCi, for
• the compound is extracted with chloroform.
• the CHC1 extracts are evaporated.
• the residue is taken up in bicarbonate water and stirred for 1/2 hour.
• the suspended compound is collected on a filter and washed with water. Melting point of 244 ° C.
• the compound is obtained according to the method described in Preparation 4, Method 1. Melting point of 314 ° C.
• the acid chloride is prepared by reaction with thionyl chloride. After evaporation of the excess reagent, the residue is taken up in 20 ml of dioxane and poured little by little onto a solution of 3.12 g of 3-amino-2-mercaptopyridine in 50 ml of dioxane with good stirring. The mixture is left to stir for 1/4 hour and then diluted by five times its volume of water. Everything goes into solution and the medium is slightly acidic, the precipitate possibly being eliminated. The pH is adjusted to around 7 with bicarbonate and allowed to crystallize. The product obtained is dried in a ventilated oven and is recrystallized from toluene if necessary. Melting point of 183 ° C.
• amide derivative 0.01 mole of the amide derivative is added to a suspension of 0.012 mole of Na tert-butoxide in 50 ml of DMF. The mixture is refluxed for 10-20 hours, the DMF is evaporated in vacuo and the residue is taken up in water (50 ml). The precipitate is filtered, washed with water and dried. Once dry, it is taken up in ether and crushed. After filtration and drying, the product can, if necessary, be recrystallized from DMF. Melting point of 305 ° C.
• N-> pyridine with N in position d)
• This compound is prepared according to the method of Preparation 8, but from 5-fluoro-2-nitrobenzoic acid and 3-amino-2-chloropyridine. Melting point of 270 ° C.
• Hal represents a halogen atom, such as Cl, F,
• the methylpiperazinoazepine salts of formula (I) can be formed by methods well known in the art. In general, these salts can be formed by the reaction in equimolecular amount of methylpiperazinoazepine with an acid in an adequate solvent, such as for example an alcohol, then optionally by precipitation of the salt by addition of another solvent miscible with the first. and in which the salt is insoluble, for example ether, or alternatively by neutralization of an ethereal solution of the acid or of the base with the base or the acid.
• the acids used are either organic acids or inorganic acids. As inorganic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, perchloric acid, etc. are preferably used.
• the organic acids are either arboxylic acids or sulphonic acids, such as acetic, citric, maleic, fumaric, propionic, glycolic, lactic, asc orbic, pamoic, succinic, tartaric, phenylacetic, benzoic, p-amino acids.
• arboxylic acids or sulphonic acids such as acetic, citric, maleic, fumaric, propionic, glycolic, lactic, asc orbic, pamoic, succinic, tartaric, phenylacetic, benzoic, p-amino acids.
• Detailed examples of the preparation of a few methylpyperazinoazepine derivatives according to the invention are given below.
• the colored mass is taken up in chloroform and washed twice with water.
• the chloroform phase is bleached with charcoal and dried. After concentration in a small volume, the mixture is passed through a silica column (Woelm act III).
• the eluting phase is acetone. Once separated, the different phases containing the product mentioned in the section are evaporated to dryness. The residue is recrystallized from petroleum 100-140. Melting point of 134 ° C.
• methylpiperazinoazepine base is prepared, mentioned in the heading according to the method of Example 2. After evaporation of the chloroformic fractions , the residue is dissolved in a minimum of boiling alcohol.
• Example 2 the compound is isolated in the form of fumarate in the same manner as in Example 3. Melting point of 260 ° C.
• Example 2 using the method of Example 2, the compound is isolated as fumarate in the same manner as in Example
• the starting material is the compound of Example 1. 15 cc of acetic anhydride are cooled and 7 cc of 99% formic acid are added thereto gradually with stirring. The mixture is brought for 15 minutes to 50 ° C. and then cooled in an ice bath. 0.02 mole of the compound of Example "1 is added and the mixture is left to stir overnight. The mixture is taken up in ice, alkalized and extracted with dichloromethane. It is dried and concentrated in vacuo, recrystallized from hexane, melting point 196 ° C.
• Example 18 We start from the compound of Example 9 and carry out the formylation according to the procedure of Example 14. Melting point of 202 ° C. Example 18
• the compound is esterified with diazomethane, which is prepared from 4 g of nitrosomethylurea by decompo ⁇ sition thereof in soda in the presence of ether.
• diazomethane is prepared from 4 g of nitrosomethylurea by decompo ⁇ sition thereof in soda in the presence of ether.
• the ethereal solution of diazomethane is gradually poured over the ethereal solution of nitric acid. Once the reaction is complete, the solvent is evaporated.
• the chloroform fractions are combined and concentrated in a small volume.
• the residue obtained is purified on a Kieselgel column with a 9/1 mixture of acetone and 40-60 petrolein as the eluting phase. Once isolated, the product is recrystallized from a mixture of dichioromethane and hexane. Melting point of 146 ° C.
• the compounds of the invention have been studied in pharmacological tests capable of revealing activity in the central or peripheral nervous system.
• the brains of male istar rats (200-250 g) are removed.
• the homogenate is centrifuged at 4 ° C at 10,000 g for 10 minutes, the pellet is washed twice with ice-cold buffer and recentrifuged.
• the method is inspired by the technique described by Yamamura and Snyder [Proc. Natl. Sci. USA 71, 1725 (1974)]. After a rapid sample, the CFY rat brain (130-180 g) is dissected to remove the cerebellum. The other tissues are homogenized with a "Potter" in a 0.32 M sucrose solution, the 50 mM Tris / HCl buffer, pH 7.5. The protein concentration is determined according to the method of Peterson [Anal. Biochem. 83, 346 (1977)].
• the binding test is carried out in triplicate at 25 ° C.
• the incubation medium (1 ml) consists of 60 mM NaCl, Tris / HCl buffer pH 7.5 and 1.5 nM ( 3 H) QNB (New En iand Nuclear, specific act: 1.18 TBq / mole).
• the reaction is maintained for 60 minutes with a homogenate containing 250-400 ⁇ g of protein.
• the non-specific binding is carried out with atropine 10 " M.
• the manipulation is stopped by rapid filtration on a Whatman GF / C glass filter. The free ligand is thus eliminated.
• Each sample is washed with 2 ⁇ 10 ml of cold buffer. Filters are dried, put in a scintillation solution and placed in a Packard Tricarb liquid scintillation counter for one day.
• the binding to the receptor is clearly proportional to the protein concentration up to 700 ⁇ g of protein per ml.
• Example 1 Example 5 + Example 7 + Example 8 +++ Example 10 +++ Example 11 +++ Example 12 + Example 13 + Example 19 ++
• Examples 1 and 3 catalepsy for doses greater than 40 mg / kg
• Clozapine weak cataleptic effect from 20 mg / kg.
• the present invention also relates to pharmaceutical compositions which contain as active constituents one or more compounds of formula (I), alone or with other active substances with similar or different effects, mixed with an appropriate pharmaceutical excipient.
• compositions can be solid, such as bare or coated tablets, in one or more layers, cachets, capsules, dispersible or soluble powders, suppositories, or liquids, such as solutions, eye drops, suspensions, emulsions, syrups, preparations intended for parenteral administration, for example in the form of an aerosol.
• the solid compositions for oral use can be prepared by mixing one or more substances in accordance with the invention, for example with milk sugar, powdered sugar, starch, talc, with products intended to retard or to prolong its effects, for example cellulose acetophthalate, glyceryl stearates, ion exchange resins.
• Suppositories can be prepared by incorporating one or more substances in accordance with the invention with cocoa butter, for example, or any other suitable substance, such as mono-, di- and triglycerides of saturated fatty acid.
• the liquid compositions can be prepared for example by dissolution, suspension or emulsion, at the time of the preparation or directly before the administration, of one or more substances in accordance with the invention and in addition of any other product whose presence is considered desirable or necessary, such as, for example, preservatives, such as methyl and propyl p-hydroxybenzoates, thickeners and emulsifiers such as cellulose derivatives and polyoxyethylene sorbitan esters, sweeteners and flavorings such as sugar, saccharin, sorbitol, natural or synthetic essences, isotonizing agents such as sodium chloride, or buffers such as sodium phosphates, in distilled water, in other acceptable hydroxylated liquids, such as ethanol , glycerin, certain glycols, in mixtures of these solvents or in pharmaceutically acceptable oils.
• preservatives such as methyl and propyl p-hydroxybenzoates
• thickeners and emulsifiers such as cellulose derivatives and polyoxyethylene sorb

Landscapes

• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Neurosurgery (AREA)
• General Health & Medical Sciences (AREA)
• Biomedical Technology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Neurology (AREA)
• Public Health (AREA)
• Psychiatry (AREA)
• Pain & Pain Management (AREA)
• Anesthesiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (12)

Applications Claiming Priority (3)

Publications (1)

Family

ID=27159764

Family Applications (1)

Country Status (14)

Cited By (5)

Families Citing this family (2)

Citations (6)

Family Cites Families (1)

• 1990
  • 1990-09-26 BE BE9000914A patent/BE1004596A4/fr not_active IP Right Cessation
• 1991
  • 1991-10-10 RU RU94021365A patent/RU2111966C1/ru not_active IP Right Cessation
  • 1991-10-10 CA CA002120229A patent/CA2120229C/fr not_active Expired - Fee Related
  • 1991-10-10 ES ES91916897T patent/ES2080336T3/es not_active Expired - Lifetime
  • 1991-10-10 DE DE69112432T patent/DE69112432T2/de not_active Expired - Fee Related
  • 1991-10-10 AT AT91916897T patent/ATE126799T1/de not_active IP Right Cessation
  • 1991-10-10 WO PCT/BE1991/000073 patent/WO1993007143A1/fr active IP Right Grant
  • 1991-10-10 DK DK91916897.1T patent/DK0607129T3/da active
  • 1991-10-10 EP EP91916897A patent/EP0607129B1/de not_active Expired - Lifetime
• 1992
  • 1992-12-23 LV LVP-92-398A patent/LV10098B/lv unknown
• 1993
  • 1993-03-03 LT LTIP378A patent/LT3231B/lt not_active IP Right Cessation
• 1994
  • 1994-10-14 EE EE9400260A patent/EE02942B1/xx not_active IP Right Cessation
• 1995
  • 1995-11-01 GR GR950403060T patent/GR3017951T3/el unknown
• 1998
  • 1998-06-23 HK HK98106195A patent/HK1006970A1/xx not_active IP Right Cessation

Patent Citations (6)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events